Elypta
Elypta is a Swedish company pioneering a metabolism-based liquid biopsy for early cancer detection. They measure the GAGome, which are system biomarkers of tumor metabolism, and use machine learning to identify non-invasive cancer signatures. The company is advancing clinical programs across various cancers, with an initial focus on early detection of recurrence in renal cell carcinoma. Their work is built on years of research from the Nielsen lab at Chalmers University of Technology. Elypta was founded in May 2017 by Francesco Gatto and Jens Nielsen. They have received significant funding, including a $21 million Series A round, and have obtained ISO 13485:2016 certification.
Elypta
Elypta is a Swedish company pioneering a metabolism-based liquid biopsy for early cancer detection. They measure the GAGome, which are system biomarkers of tumor metabolism, and use machine learning to identify non-invasive cancer signatures. The company is advancing clinical programs across various cancers, with an initial focus on early detection of recurrence in renal cell carcinoma. Their work is built on years of research from the Nielsen lab at Chalmers University of Technology. Elypta was founded in May 2017 by Francesco Gatto and Jens Nielsen. They have received significant funding, including a $21 million Series A round, and have obtained ISO 13485:2016 certification.
TL;DR
Founded: 2017 (co‑founders Francesco Gatto and Jens Nielsen)
Product: Metabolism‑based liquid biopsy that measures the GAGome (glycosaminoglycans) and uses machine learning to detect cancer signatures
Clinical focus: Renal cell carcinoma recurrence monitoring; development toward multi‑cancer early detection
Regulatory / quality: ISO 13485:2016 certified for IVD test kits and associated software
Selected funding: Series A $21M (Jun 2022); late seed €6.1M (Dec 2019); EU Horizon 2020 grant €2.35M (2019)
Karolinska Institute campus, Solna/Stockholm, Sweden
Company Overview
Problem Domain
Early cancer detection and post‑treatment recurrence monitoring (primary clinical focus on renal cell carcinoma; longer‑term multi‑cancer early detection goals).
Founded
2017
Industry
Molecular diagnostics
Tech Stack
Funding Track Record
€2.35M
EU grant award
€6.1M
Round closed Dec 2019 (announced Jan 23, 2020); participants disclosed include Norrsken Foundation (impact fund), Nina Capital, Chalmers Ventures
$21M
Announced June 20, 2022
Crunchbase indicates a grant round dated Mar 28, 2023; specific amount not stated in provided evidence
Investor Signal
“Backed by European investors including Bonnier Ventures (Series A) and Industrifonden (late seed); other disclosed participants include Sciety, Norrsken Foundation (impact fund), Nina Capital, Chalmers Ventures, and institutions listed on Crunchbase such as The Roddenberry Foundation and Navigare Ventures.”